Engineered Immune Cells for High-Specificity Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor markers for cancer detection, such as CA125 and CA19-9, have low specificity and high false-positive and false-negative rates due to their expression in normal cells, making early detection of primary cancer challenging.
Innovation Solution
The use of immune cells, specifically T cells engineered to express detectable markers upon activation, which are administered to patients and labeled with radiotracers or fluorescent agents to localize and detect altered cells, including cancer cells, through binding to specific antigens associated with cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional tumor markers (CA125, CA19-9) are used for cancer detection, then the detection method is simple and widely available, but the specificity is low and false-positive/negative rates are high
Solution Approach 1:
The patent introduces engineered immune cells as intermediary agents that specifically recognize and bind to tumor antigens. These cells act as mediators between the detection system and target cells, enabling high-specificity cancer detection through their antigen-specific receptors while carrying detectable labels for signal generation
Solution Approach 2:
The patent changes the detection parameter from measuring soluble tumor markers in serum to detecting activated immune cells that have bound to tumor cells. This parameter change from chemical marker concentration to cellular interaction detection fundamentally improves specificity by utilizing the immune system's natural ability to distinguish altered self from normal self
2Measurement precision
If immune cells are engineered to express detectable markers upon activation, then cancer detection specificity is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent performs preliminary engineering of immune cells ex vivo before administration, where the cells are pre-loaded with detectable labels and configured with activation-dependent expression systems. This preliminary action allows the complex manufacturing process to be completed before clinical use, simplifying the actual detection procedure
Solution Approach 2:
The engineered immune cells are designed to automatically activate and express detectable markers only when they encounter and bind to their specific tumor antigens in vivo. This self-service mechanism eliminates the need for external activation or complex real-time processing, allowing the cells to autonomously perform the detection function
3Reliability
If labeled immune cells are administered to detect altered cells, then early cancer detection capability is enhanced, but the cost and complexity of the procedure increases
Solution Approach 1:
The engineered immune cells serve multiple functions simultaneously: they specifically recognize tumor antigens through their receptors, provide signal amplification through detectable labels, and can potentially exert therapeutic effects through immune activation. This multi-functionality consolidates detection and potential therapy into a single agent, reducing overall procedural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the accuracy of cancer detection by selectively targeting and identifying altered cells, reducing false positives and negatives, and allows for both localization and potential therapeutic intervention.
Implementation Method 1
obtaining a population of immune cells capable of activation subsequent to binding to one or a plurality of antigens on the altered cell
Implementation Method 2
labeled with radiotracers or fluorescent agents to localize and detect altered cells
Implementation Method 3
labeled with radiotracers or fluorescent agents to produce a detectable signal
Data Source
AI summary
Disclosed are methods, compositions of matter, and protocols useful for the detection of altered cells in a patient. Immune cells capable of clonal expansion are engineered to produce a soluble signal upon activation and/or clonal expansion. The cells may possess a suicide gene, inducible upon administration pharmacological or light/radiation activatable, so as to eliminate the cells from body when desired. In another embodiment, immune cells produce a localized marker, the marker being visible with imaging technology. In other embodiments cells capable of non-clonal expansion are utilized. The disclosure provides means of utilizing the immunosurveillance properties of immune cells to diagnose and localize diseases associated with alteration of host cells.